



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



ZG-2033

Item No. 41672

CAS Registry No.: 2685739-28-8
Formal Name: N-(3,5-dimethoxyphenyl)-1,2-benzisothiazol-3-amine
MF: C₁₅H₁₄N₂O₂S
FW: 286.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ZG-2033 is supplied as a solid. A stock solution may be made by dissolving the ZG-2033 in the solvent of choice, which should be purged with an inert gas. ZG-2033 is slightly soluble (0.1-1 mg/ml) in acetonitrile and sparingly soluble (1-10 mg/ml) in DMSO.

Description

ZG-2033 is an agonist of hypoxia-inducible factor 2α (HIF-2α).¹ It induces HIF-2α transcriptional activity in a reporter assay using 786-O cells expressing HIF-2α (EC₅₀ = 0.49 μM). ZG-2033 (10 or 50 μM), in combination with the inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2) and HIF-PH3 AKB-6548 (vadadustat; Item No. 15295), increases the number of erythrocytes in a zebrafish model of doxorubicin-induced anemia. It increases the plasma levels of erythropoietin (EPO) in mice when administered at concentrations of 100 or 200 mg/kg in combination with vadadustat.

Reference

1. Yu, Y., Yang, F., Yu, Q., *et al.* Discovery of a potent and orally bioavailable hypoxia-inducible factor 2α (HIF-2α) agonist and its synergistic therapy with prolyl hydroxylase inhibitors for the treatment of renal anemia. *J. Med. Chem.* **64**(23), 17384-17402 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/23/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM